

Detection of *ebaf*, a Novel Human Gene of the Transforming Growth Factor β Superfamily

Association of Gene Expression with Endometrial Bleeding

Ravi Kothapalli,* Ibrahim Buyuksal,* Shi-Qi Wu,† Nasser Chegini,§ and Siamak Tabibzadeh*

*Department of Pathology, Moffitt Cancer Center, Tampa, Florida 33612; †University of Wisconsin, Comprehensive Cancer Center, Madison, Wisconsin 53792; and §Department of OB/GYN, University of Florida at Gainesville, Gainesville, Florida 32610

Abstract

Human endometrium is unique since it is the only tissue in the body that bleeds at regular intervals. In addition, abnormal endometrial bleeding is one of the most common manifestations of gynecological diseases, and is a prime indication for hysterectomy. Here, we report on a novel human gene, endometrial bleeding associated factor (*ebaf*), whose strong expression in endometrium was associated with abnormal endometrial bleeding. In normal human endometrium, this gene was transiently expressed before and during menstrual bleeding. In situ hybridization showed that the mRNA of *ebaf* was expressed in the stroma without any significant mRNA expression in the endometrial glands or endothelial cells. The predicted protein sequence of *ebaf* showed homology with and structural features of the members of TGF- β superfamily. Fluorescence in situ hybridization showed that the *ebaf* gene is located on human chromosome 1 at band q42.1. Thus, *ebaf* is a novel member of the TGF- β superfamily and an endometrial tissue factor whose expression is associated with normal menstrual and abnormal endometrial bleeding. (*J. Clin. Invest.* 1997; 99:2342–2350.) Key words: human • endometrium • endometrial bleeding • *ebaf* • TGF- β

Introduction

Normal menstruation, a unique process of endometrial tissue shedding and bleeding, is a complex phenomenon that occurs during the reproductive years in women, some higher primates, and two nonprimate species; the elephant shrew (*Elephantus myurus jamesoni*) and the bat (*Glossophaga soricina*) (1). This process is associated with breakdown and loss of upper layers of endometrium (functionalis) consisting of glands and their surrounding stroma after a normal ovarian cy-

cle. The role of steroid hormones as the primary and systemic force that drives the endometrium through the exquisitely orchestrated phases of the menstrual cycle is well recognized (2, for recent reviews see references 3–5). The elegant studies of Markee demonstrated that withdrawal from steroid hormones is responsible for the menstrual shedding of endometrium and bleeding (2). Any aberration in the priming of endometrium by estrogen followed by progesterone leads to premature and sometimes excessive bleeding during the menstrual cycle or during menstruation. This abnormal endometrial bleeding is one of the most common disorders in women, and is one of the primary causes for hysterectomy (6). During the reproductive years, nearly 20% of women exhibit menorrhagia (excessive blood loss during menstruation) (7, 8), and almost every woman during her lifetime experiences episodes of abnormal endometrial bleeding (6). The primary conditions that are associated with deranged priming of endometrium by the steroid hormones include aberrant follicular maturation, ovulation or development of corpus luteum (6, 9, 10), and administration of steroid hormones, including progestagens (9, 11–13). The underlying basis for dysfunctional uterine bleeding, a common gynecological disorder that affects women during the reproductive years, is also due to an inappropriate exposure of endometrium to steroid hormones. In most cases, this condition is almost always associated with anovulatory cycles, and occurs from a proliferative endometrium (6, 10). More than 75% of abnormal endometrial bleeding in adolescents is dysfunctional uterine bleeding due to immaturity of the hypothalamic-pituitary-ovarian axis. As a result of lack of luteinizing hormone surge and anovulation, the endometrium is continuously exposed to estrogen, and the progesterone-dominated secretory phase does not develop (10). The dysfunctional uterine bleeding in perimenopausal women has a similar basis. The aging ovary does not produce an adequate amount of estrogen to induce the midcycle surge of luteinizing hormone. In these adolescents and perimenopausal women, the endometrium is continuously exposed to estrogen, and bleeding is thought to occur as a result of this unopposed estrogen exposure (9). On the other hand, dysfunctional uterine bleeding may occur during the secretory phase, due to, for example, an inadequate luteal phase (9). Bleeding which occurs as spotting or breakthrough-bleeding, or occasionally as heavy bleeding, may happen while the steroid hormones are being administered as a therapeutic measure or for contraception (9, 11–13). Despite the knowledge that steroid hormones are responsible for normal and abnormal endometrial bleeding, the identity of the local and specific endometrial factors which are implicated remain largely unrecognized. Endometrium is a unique tissue,

Address correspondence to S. Tabibzadeh, M.D., Department of Pathology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. Phone: 813-979-7237; FAX: 813-979-3085; E-mail: tabibzadeh@moffitt.usf.edu

Received for publication 27 November 1996 and accepted in revised form 26 February 1997.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/97/05/2342/09 \$2.00

Volume 99, Number 10, May 1997, 2342–2350

since other tissues, such as breast, despite the expression of steroid hormone receptors and response to these hormones, do not bleed at the time when the serum levels of steroid hormones have fallen and endometrium is menstruating. This fact suggests that there should be tissue-specific factors that make endometrium susceptible to bleeding. Here, we report on a novel human gene of the TGF- β superfamily whose expression in endometrium is confined to both the late secretory phase and during endometrial bleeding.

Methods

Materials. The differential display kit (RNA image kit) was obtained from GenHunter Corporation (Brookline, MA). pBluescript[®] SK⁻ and human placental cDNA library were purchased from Stratagene Inc. (La Jolla, CA). A 1.1-kb cDNA fragment of GAPDH (glyceraldehyde 3-phosphate dehydrogenase)¹ was obtained from Clontech (Palo Alto, CA). Reagent kit for sequencing with sequenase and Hybond nylon membrane were from Amersham Corp. (Arlington Heights, IL). Deoxycytidine 5' triphosphate dCTP α -³²P (3,000 Ci/mmol) was from Dupont-NEN (Boston, MA). Prime-a-Gene labeling kit was from Promega Corp. (Madison, WI). RNA STAT-60[™] was from Tell-Test, Inc. (Friendswood, TX). Silane-coated, RNase-free slides coated (Silane-Prep[™]) for in situ hybridization and the Kodak-OMAT films were obtained from Sigma Chemical Company (St. Louis, MO). Nick columns were obtained from Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Digoxigenin labeling kit (SP6/T7) and DIG nucleic acid detection kit were from Boehringer Mannheim Biochemicals (Indianapolis, IN). All other chemicals were from either Sigma Chemical Company or Fisher Scientific Co. (Pittsburgh, PA).

Processing of endometria. Endometrial tissues were obtained as biopsy or curettings from hysterectomy specimens of normal fertile women who underwent these procedures for nonendometrial abnormalities such as ovarian or cervical lesions. In addition, endometrial samples were obtained from a group of patients with endometrial bleeding. The age, menstrual cycle history, date of endometrium, type of bleeding, and other associated clinical findings in these patients are presented in Table I. The endometria of these patients, consistent with anovulatory and ovulatory cycles exhibited a proliferative and secretory pattern, respectively. In patients whose endometrium had a proliferative pattern, bleeding was the major reason for hysterectomy (see Table I). Hysterectomy specimens and each endometrial biopsy sample were rapidly processed. The date of endometrium was determined based on the morphologic evaluation of hematoxylin and eosin-stained endometrial sections using established criteria of Noyes and Hertig (14). Each endometrial sample was aliquoted as required. Most tissues, however, were used as follows: ~ 10% of each sample was processed for paraffin sectioning and morphologic examination; ~ 70% was flash frozen in a dry ice/ethanol bath for isolation of RNA; and the remaining 20% was frozen in OCT mounting medium (Tissue-Tek II; Miles Laboratories, Inc., Naperville, IL) for cryostat sectioning and in situ hybridization studies.

Differential display. Differential display was performed as described (15, 16). Briefly, cDNA synthesis was carried out using an anchored oligo-(dT). The quality of cDNA was verified by PCR using gene-specific primers to actin which would produce a specific product of defined length detectable by agarose gel electrophoresis. The templates for differential display consisted of cDNAs prepared from total RNAs isolated from endometria from various phases of the menstrual cycle. These included two cases of proliferative endometria, three cases of postovulatory day 5 endometria, one case of postovulatory day 12 endometrium, one case of postovulatory day 14 en-

dometrium, and one case of menstrual endometrium. The cDNAs were amplified with several primer sets. The amplified products from different cDNAs were size-fractionated on a denaturing polyacrylamide gel. Several amplified products were differentially expressed throughout the menstrual cycle. The primer set consisting of an anchored oligo-(dT) (AAG CTT TTT TTT TTT C) and an arbitrary primer (AAG CTT GAT TGC C) led to the identification of two differentially expressed PCR products. One of these products, present in the late secretory/menstrual endometria, was removed from the sequencing gel from the lane that contained the amplified products from postovulatory day 12. This band was reamplified, and was run on a sequencing gel along with the amplified product of the postovulatory day 12 sample. The mobility of the reamplified band was the same as that seen in the amplified product from the postovulatory day 12 sample. The cDNA of the reamplified product was cloned using a T-tailed vector (pBluescript II KS⁻) (17, 18). To assure that the cloned product is derived from the same gene, seven independent clones were sequenced (19), and were found to contain an identical 300-bp sequence.

Isolation of RNA and Northern blotting. The RNA was extracted by using acid guanidinium thiocyanate-phenol-chloroform extraction method as described (20). Briefly, the tissues were homogenized in RNA STAT-60[™]. Each 50–100 mg of tissue was homogenized in 1 ml of RNA STAT-60[™] in a glass or Teflon Dounce homogenizer. Each homogenate was stored for 5 min at room temperature to permit the complete dissociation of nucleoprotein complexes. Then, 0.2 ml of chloroform was added for each milliliter of RNA STAT-60[™] used. Each sample was covered and shaken vigorously for 15 s, and allowed to stand at room temperature for 2–3 min. After centrifugation at 12,000 g for 15 min at 4°C, each homogenate was separated into a lower phenol/chloroform phase and an upper aqueous phase. RNA in the upper aqueous phase was transferred to fresh tubes and mixed with isopropanol to precipitate the total RNA. After centrifugation and drying, the precipitated RNA was dissolved in diethylpyrocarbonate (DEPC)-treated water by vigorous pipetting and by a gentle heating at 55–60°C. The amount of RNA in each sample was determined spectrophotometrically, and its quality was evaluated by the integrity of ribosomal RNA by electrophoresis of 20 μ g of total RNA in 1% formaldehyde-agarose gel in the presence of ethidium bromide. Northern blotting was done as described (21). Briefly, 20 μ g of total RNA of each sample was denatured at 65°C in a RNA loading buffer, electrophoresed in 1% agarose containing 2.2 M formaldehyde gel, and blotted onto a Hybond nylon membrane using a positive pressure transfer apparatus (Posiblot; Stratagene Inc.). The RNA was fixed to the membrane by UV crosslinking. Using the Prime-a-Gene kit, cDNA was labeled with [³²P] to a high specific activity, and purified by Nick columns. Membranes were prehybridized in 50% formamide, 10 \times Denhardt's solution, 4% saline sodium citrate (SSC), 0.05 M sodium pyrophosphate, and 0.1 mg/ml of denatured herring sperm DNA at 42°C for 2–4 h and hybridized for 16 h at 42°C with 10⁶ cpm/ml of heat-denatured probe in the same buffer containing 10% dextran sulphate. Then, membranes were sequentially washed three times in 4 \times SSC, one time in 0.5 \times SSC, and then one time in 0.1 \times SSC. All washes contained 0.1% sodium dodecyl sulphate (SDS), and were done at 65°C for 20 min each. The membranes were subjected to autoradiography at –70°C with intensifying screens. The same blot was stripped and reprobed for GAPDH. To reprobe a blot, the probe was stripped from the membrane in 75% formamide, 0.1 \times saline sodium phosphate ETDA (SSPE), and 0.2% SDS at 50°C for 1 h. The relative abundance of mRNA in each band in the autoradiograms was quantitated by laser scanning densitometry. The relative optical densities of the GAPDH bands were used to normalize the relative optical densities of the bands from the *ebaf* mRNA.

In situ hybridization. Digoxigenin-labeled sense and antisense RNAs of *ebaf* were synthesized by in vitro transcription of the full-length cDNA cloned into pBluescript[®] SK⁻ using digoxigenin dUTP. After alkaline hydrolysis, the probes were subjected to agarose gel electrophoresis to determine the size of the digested RNA fragments.

1. Abbreviation used in this paper: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.




Figure 1. Northern blot analysis of *ebaf* in human endometrium throughout the menstrual cycle. (Top) 20 μ g total RNA from each endometrium was subjected to Northern blot analysis using a 300 bp at the 3' end of the *ebaf* cDNA, or the entire cDNA as the probe. As shown, a band of mRNA in the size of 2.5 kilobase (kb) was detected only in the late secretory and menstrual endometria. The *ebaf* mRNA was not detectable in endometrium during the proliferative phase, or in early (postovulatory days 1–5) or midsecretory (postovulatory days 6–8) phases of the menstrual cycle. The integrity of RNA and equal loading was verified by staining the 18s and 28s ribosomal RNAs (not shown) and hybridization of the blots with a probe to GAPDH. MP, mid proliferative; LP, late proliferative.

tive. (Bottom) The relative optical densities of the *ebaf* and GAPDH mRNA bands were determined by laser scanning densitometry. The bottom panel shows the relative optical density ratios of the *ebaf*/GAPDH bands.

Dot blotting was performed on the RNA fragments to assure that they were labeled. In situ hybridization was performed as previously described (22, 23). Briefly, frozen sections of endometria were mounted on silane-coated RNase-free slides, and fixed in 4% formalin in PBS for 15 min at 4°C. The tissue sections were rinsed in 2× SSC and then treated with proteinase K (1 μ g/ml in 0.1 M Tris, 50 mM EDTA, 20 min, 37°C) and acetylated for 10 min in 0.1 M triethanolamine (pH 8.0), 0.9% sodium chloride, and 0.25% acetic anhydride. The slides were dipped once in 2× SSC, and then were dehydrated in ascending series of ethyl alcohol, and air-dried. The slides were pre-hybridized for 1 h at 37°C in 50% formamide, 1× Denhardt's solution, and 500 μ g/ml tRNA, 0.3 M sodium chloride, 10 mM Tris, 1 mM EDTA (pH 8), and 10% dextran sulfate. Then, sections were incubated at 55°C overnight in the same solution containing the appropriate concentration of the probe. The amounts of labeled probes needed were empirically determined first by a series of in situ hybridization experiments using various dilutions of the probes. Sense probe was used as the control. After hybridization, slides were washed three times for 10 min each at room temperature in 2× SSC, and the excess SSC was removed. The sections were then incubated with RNase A (20 μ g/ml) in 500 mM NaCl, 1 mM EDTA, and 10 mM Tris-HCl (pH 8) at 37°C for 30 min to remove the nonhybridized RNA. The sections were washed three times at room temperature, for 15 min each, in 2× SSC, 1× SSC, and 0.5× SSC and a final wash in 0.1× SSC at 55°C for 45 min. Slides were washed in 100 mM Tris (pH 8), 150 mM sodium chloride for 10 min. Then, the sections were blocked in 5% normal horse serum in the same buffer for 20 min at 37°C. Slides were incubated with alkaline phosphatase-labeled, anti-digoxigenin antibody for 1 h at 37°C, washed, and developed in a mixture of Nitroblue tetrazolium salt (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP).

Metaphase cell preparation and fluorescence in situ hybridization (FISH). Metaphase spreads were obtained from PHA-stimulated lymphocytes of normal human peripheral blood. G-banding was performed on air-dried slides after they were aged for 1 wk. The banded metaphase chromosomes were examined and photographed with a MAX-BX 40 Olympus microscope using a UWplan FL \times 100 objective (dry lens). The coordinates of each metaphase were recorded. The slides were then destained with two changes of 3:1 methanol/acetic acid for 5 min each, and air-dried. The full length *ebaf* cDNA was used as the probe in the FISH.

Results and Discussion

Identification of *ebaf* by differential display. We were interested in testing the hypothesis of whether gene(s) exist whose expression in endometrium is confined to the premenstrual/menstrual period. We reasoned that the genes that are involved in the process of menstrual bleeding potentially will be expressed immediately before and during menstruation. To test the hypothesis, we used differential display and looked for gene(s) whose expression in endometrium was confined to the late secretory/menstrual phase. We identified a major band in the differential display gel whose expression, consistent with our hypothesis, was found in postovulatory days 12 and 14 and the menstrual endometria. A GenBank nucleotide BLAST search revealed the sequence of this band to be 100% identical to the expressed sequence tag (EST) cDNA clone 137335 3' that has been derived from human placenta. To obtain the full-length coding sequence of this gene, we screened a human placental




Figure 2. Northern blot analysis of *ebaf* mRNA expression in normal tissues. (Top) 20 μ g total RNAs from normal tissues was subjected to Northern blot analysis using the full-length *ebaf* cDNA as the probe. The integrity of RNA was verified by staining the 18S and 28S ribosomal RNA

(not shown) and hybridization of the blots with a cDNA probe to GAPDH. The tissues in lanes 1–12 were, respectively, as follows: lung, kidney, ovary, liver, colon, rectum, spleen, lymph node, pancreas, testis, stomach, and stomach mucosa. Lane 13 is a positive control RNA sample from endometrium of a patient with endometrial bleeding showing the *ebaf* mRNA band (see Fig. 4). Whereas GAPDH mRNA was detected in these tissues, the *ebaf* mRNA was not detectable in tissues other than endometrium.




Figure 3. In situ hybridization of *ebaf* mRNA in normal human endometrium. Sections of late secretory endometria exhibited hybridization signals with digoxigenin-labeled, antisense, *ebaf* RNA probe in the stroma (A, $\times 50$; B, $\times 200$). On the other hand, sections of late proliferative endometria failed to show any hybridization signal with the antisense *ebaf* RNA probe (C, $\times 50$; D, $\times 200$). Endothelial cells did not exhibit hybridization signals with the digoxigenin-labeled, antisense *ebaf* RNA in secretory (A and B) or proliferative (C and D) endometria (arrows).

library with the 300-bp fragment. Three independent clones with a 2.0-kb cDNA insert were identified and sequenced in both directions, and cDNA of one of these clones (*ebaf*) was used in the following studies.

Expression of ebaf mRNA in normal human endometrium throughout the menstrual cycle. Northern blot analysis showed

that in normal human endometrium, the expression of the *ebaf* mRNA was menstrual cycle phase-specific. The *ebaf* mRNA in human endometrium was transiently expressed in the late secretory/menstrual phase (Fig. 1). The size of the *ebaf* mRNA species detected in all endometria was ~ 2.5 kb (Fig. 1). The expression of *ebaf* mRNA could not be detected in endometria

Table I. Characteristics of Patients with Endometrial Bleeding

Case no.	Age	Menstrual cycle history		Date of endometrium	Characteristics of bleeding	Other clinical findings
		Regular	Irregular			
1	40		Y	P	Menometrorrhagia*	Endometriosis
2	37	Y		P	Menorrhagia* (2 yr)	
3	34	Y		P	Menorrhagia*	
4	35	Y (8–12 d)		P	Menorrhagia*	Ovarian cyst, adhesions
5	39		Y	P	Menometrorrhagia*	Adenomyosis
6	28		Y (8–9 d)	P	Menometrorrhagia*	CINIII
7	45		Y	P	Severe menometrorrhagia, uncontrolled*	Adenomyosis, pelvic pain
8	36	Y		MS	Menometrorrhagia	Leiomyoma
9	43	Y		ES	Menometrorrhagia	Leiomyoma
10	22	Y		MS	Menometrorrhagia	CINIII
11	44	Y		MS	Menometrorrhagia	Ovarian cyst
12	43	Y		ES	Menometrorrhagia	Leiomyoma

Y, yes; P, proliferative, ES, early secretory; MS, midsecretory; LS, late secretory. *Endometrial bleeding was the major reason for hysterectomy.




Figure 4. Northern blot analysis of *ebaf* mRNA expression in endometria of patients with endometrial bleeding. (Top) 20 µg total RNAs from endometria of patients with endometrial bleeding was subjected to Northern blot analysis using the full-length *ebaf* cDNA as the probe. The integrity of RNA was verified by staining the 18s and 28s ribosomal RNA (not shown) and hybridization of the blots with a cDNA probe to GAPDH. The endometria were dated to the proliferative, early, and midsecretory phases. The mRNA of *ebaf* is strongly expressed in all endometria irrespective of whether the endometrium was in the proliferative or secretory phase of the menstrual cycle. In most patients with endometrial bleeding, no organic lesions that could account for the bleeding were detected. Three patients had leiomyomata (lanes 8, 9, and 12 from left). (Bottom) The relative optical densities of the *ebaf* and GAPDH mRNA bands were determined by laser scanning densitometry. The bottom shows the relative optical density ratios of the *ebaf*/GAPDH bands.

in the proliferative or early and midsecretory phases of the menstrual cycle (Fig. 1). Northern blot analysis failed to reveal the presence of 2.5 kb *ebaf* mRNA in a number of normal tissues including lung, kidney, ovary, liver, colon, rectum, spleen, lymph node, pancreas, testis, and stomach (Fig. 2).

In situ hybridization confirmed the findings of Northern blot analysis. Sections of late secretory endometria exhibited hybridization signals with the antisense *ebaf* RNA probe in the stroma. Within stroma, the mRNA expression was confined to predecidualized stromal cells in the upper layers of endometrium underlying the surface epithelium (Fig. 3, A and B). In the same endometria, the stroma in the basal part of the endometrium overlying the myometrium failed to exhibit evidence of mRNA expression (data not shown). In these endometria, with exception of a few glands located near the surface epithelium, virtually no *ebaf* mRNA expression could be identified in the epithelial cells. On the other hand, sections of late proliferative endometria failed to show any hybridization signal with the antisense *ebaf* RNA probe (Fig. 3, C and D). Endothelial cells (arrows, Fig. 3, A–D) did not exhibit hybridization signals with the antisense *ebaf* probe. All endometria exhibited hybridization signals with a digoxigenin-labeled antisense GAPDH RNA probe, but not with the sense *ebaf* RNA probe (data not shown). This finding suggests that expression of *ebaf* mRNA occurs primarily in stromal cells that have been predecidualized. The Northern blot and in situ hybridization data suggest that the expression of *ebaf* in the human endometrial stroma may be considered as part of the premenstrual/

Table II. The Extent of Identity and Similarity Between the *ebaf* and Other Members of the TGF-β Superfamily

Name of gene	% Identity	% Similarity
<i>ebaf</i>	100	100
lefty	77	83
MIS	26	68
TGF-β ₃	25	65
BMP-7	25	64
TGF-β ₁	23	65
INH-β B chain	23	63
BMP-3	23	64
GDF-9	22	64
GDF-3	21	60
INH-β A chain	20	65

The deduced amino acid sequence of *ebaf* was aligned with the amino acid sequences of various members of the TGF-β superfamily using the CLUSTAL program, and the percent identities and similarities were calculated (32). Except for lefty, GDF-3, and GDF-9, all other sequences were from humans. *ebaf*, endometrial bleeding associated factor; *MIS*, müllerian inhibiting factor precursor; *TGF-β₁*, transforming growth factor β₁ precursor; *BMP-7*, bone morphogenetic protein-7 precursor; *TGF-β₃*, transforming growth factor β₃ precursor; *INH-β A*, inhibin-β A chain precursor; *GDF-9*, growth differentiation factor-9; *GDF-3*, growth differentiation factor-3.

menstrual molecular repertoire which is expressed before and during menstrual shedding.

Expression of *ebaf* mRNA in endometria of patients with endometrial bleeding. The findings suggested that the *ebaf* expression may be closely associated with endometrial bleeding. To validate this hypothesis, endometria were obtained from a group of patients with endometrial bleeding. Dating of these endometria showed some to be in the proliferative phase, and others to be in the secretory phase (Table I). In most patients, organic lesions that could account for the endometrial bleeding could not be found. In three patients, however, the endometrial bleeding was associated with the presence of uterine leiomyoma (Table I). The mRNA of *ebaf* was strongly expressed in endometria of these women (Fig. 4). Interestingly, the expression of mRNA of *ebaf* was observed in endometrium regardless of whether the bleeding endometrium was in the proliferative, early, or midsecretory phases of the menstrual cycle when no expression of the gene was expected. These findings validate the hypothesis that endometrial bleeding is associated with the expression of *ebaf* mRNA in human endometrium.

Characterization of full-length *ebaf* cDNA. In view of these findings, the clones containing the longest cDNAs of *ebaf* were isolated from a placental library and sequenced (19). Within the *ebaf* cDNA, a consensus polyadenylation signal was present eight bases upstream from the poly-A tail (Fig. 5). GenBank search revealed that the deduced amino acid sequence of *ebaf* shows a great amount of identity and similarity with the known members of the TGF-β superfamily (Table II). The predicted protein sequence of *ebaf* showed a strong homology to the mouse lefty/stra3 (24, 25). The deduced amino acid sequence of *ebaf* protein is 77% identical and 83% similar to lefty protein (Fig. 6). A motif search revealed that the pre-

1 CCACTCTGCCTCCTGCTCCCCAGGGCAGCACCATGTGGCCCTGTGGCTCTGCTGGGCACTCTGGGTGCTGCCCTGGCTGGCCCCGGGGCG
M W P L W L C W A L W V L P L A G P G A 20

94 GCCCTGACCGAGGAGCAGCTCCTGGCGAGCCTGCTGCGGCAGCTGCAGCTCAGCGAGGTGCCCGTACTGGACAGGGCCGACATGGAGAAGCTG
A L T E E Q L L A S L L R Q L Q L S E V P V L D R A D M E K L 51

187 GTCATCCCCGCCACGTGAGGGCCAGTATGTAGTCTGCTGCGGCGCGACGGGGACCGCTCCCGCGAAAGAGGTTTCAGCCAGAGCTTCCGA
V I P A H V R A Q Y V V L L R R D G D R S **R G K R** F S Q S F R 82

280 GAGGTGGCCGGCAGGTTCTGGCGTCGGAGGCCAGCACACCTGTGGTGTTCGGCATGGAGCAGCGGCTGCCGCCCAACAGCGAGCTGGTG
E V A G R F L A S E A S T H L L V F G M E Q R L P P N S E L V 113

373 CAGGCGTGTGCGGCTCTCCAGGAGCCGGTTCCTCAAGGCGCGTGCACAGGCACGGGCGGCTGTCCCGGCGAGCGCCCAAGGCCCGGGTG
Q A V L R L F Q E P V P Q G A L H **R H G R** L S P A A P K A R V 144

466 ACCGTGAGTGGCTGGTCCGCGACGACGGCTCCAACCGCACCTCCCTCATCGACTCCAGGCTGGTGTCCGTCCACGAGAGCGGCTGGAAGGCC
T V E W L V R D D G S **R** T S L I D S R L V S V H E S G W K A 175

559 TTCGACGTGACCGAGGCCGTGAACCTTCTGGCAGCAGCTGAGCCGGCCCCCGAGCCGCTGCTCGTACAGGTGTGGTGACAGGGAGCATCTG
F D V T E A V N F W Q Q L S R P P E P L L V Q V S V Q R E H L 206

652 GGCCCGCTGGCGTCCGCGCGCCACAAGCTGGTCCGCTTTCCTCGCAGGGGGCGCCAGCCGGGCTTGGGGAGCCCCAGCTGGAGCTGCACACC
G P L A S G A H K L V R F A S Q G A P A G L G E P Q L E L H T 237

745 CTGGACCTCAGGGACTATGGAGCTCAGGGCGACTGTGACCCCTGAAGCACCAATGACCGAGGGCACCCGCTGCTGCCGCCAGGAGATGTACATT
L D L R D Y G A Q G D C D P E A P M T E G T R C C R Q E M Y I 268

838 GACCTGCAGGGGATGAAGTGGGCCAAGAACTGGGTGCTGGAGCCCCGGGCTTCTGGCTTACGAGTGTGTGGGCACCTGCCAGCAGCCCCCG
D L Q G M K W A K N W V L E P P G F L A Y E C V G T C Q Q P P 299

931 GAAGCCCTGGCCTTCAATTGGCCATTCTGGGGCCGCGACAGTGTATCGCTCGGAGACTGCCTCGCTGCCCATGATCGTCAGCATCAAGGAG
E A L A F N W P F L G P R Q C I A S E T A S L P M I V S I K E 330

1024 GGAGGCAGGACAGGCCCCAGGTGGTCAGCCTGCCAACATGAGGGTGCGAAGTGCAGCTGTGCCTCGGATGGGGCGCTCGTGCCAAGGAGG
G G R T R P Q V V S L P N M R V Q K C S C A S D G A L V P R R 361

1117 CTCCAGCATAGGCCCTGGTGTATCCATTGAGCCTCTAACTGAACGTGTGCATAAGAGGTGGTCTTAATGTAGGGCGTTAACTTTATACTTAGC
L Q H R P W C I H * 370

1210 AAGTTACTCCATCCCAATTTAGTGTCTGCTGACCTCGCCCTGTGTCTTCCATTCTGTCTTCCCGTCCATCACCCATCCTAAGCACTT
1303 ACGTGAGTAAATAATGCAGCTCAGATGCTGAGCTCTAGTAGGAAATGCTGGCATGCTGATTACAAGATACAGCTGAGCAATGCACACATTTTC
1396 AGCTGGGAGTTTCTGTCTCTGCGCAAATTTCTCACTGAGTCTGGAACAATAATACCCCTATGATTAGAAGTGGGGAAACAGAACTGAATTGCTG
1489 TGTATATAGGAATTAACCTTCAAATCTCTATTTCCTCCCAAATACTGACCCATTCTGGACTTTGTAAACATACCTAGGCCCTGTGCC
1582 CTGAGAGGGTGTAAAGAGGAAGGATGAAGGGCTTCAGGCTGGGGGCGAGTGACAGGGAATTTGGGATACCTGGATTCTGGTTCTGACAGGGCCA
1675 CAAGCTAGGATCTCTAACAAACGAGAAAGGCTTGGCTCGTCATTTCCTCTAAAAAAGGAGGAGCTGGGCTTCAGCTCTAAGAAGTTTCATTG
1768 CCCTGGGGATCAGACAGCCCTACCTACCCCTGCCACTCCTCTGGAGACTGAGCCTTGCCCGTGCATATTTAGGTTCATTTCCACACTGTCT
1861 TAGAGAACTGTACCAGAAACCATGTATTGTCATGTTTTTTGTTAATTTAGCTAAAGCAATTGAATGTAGATACTCAGAGAAATAAAAA
1954 ATGATGTT

Figure 5. Nucleotide and deduced amino acid sequences of *ebaf*. The nucleotide sequence of *ebaf* contained an open reading frame with an initial methionine codon that conformed to the Kozak consensus (GCACCATG) sequence (32). The potential signal peptide is underlined, the putative tetrabasic processing sites (**RGKR** and **RHGR**) are shown in bold, and the potential glycosylation site is circled (arrow). A consensus polyadenylation signal (**AATAAA**) was present eight bases upstream from the poly-A tail of *ebaf* cDNA. The sequence was deposited in GenBank database under accession number; Bankit84646□U81523.

dicted *ebaf* protein contains most of the cysteine residues which are conserved among the TGF- β -related proteins (26), and which are necessary for the formation of the cysteine knot structure (27, 28) (Fig. 7). The *ebaf* sequence contains an additional cysteine residue, 12 amino acids upstream from the first conserved cysteine residue. The only other family members known to contain an additional cysteine residue are TGF- β s, inhibins, and GDF-3 (26, 29). *ebaf*, similar to lefty, GDF-3/Vgr2, and GDF-9, lacks the cysteine residue that is known to form the intermolecular disulfide bond (29, 30). Therefore, *ebaf* appears to be an additional member of the TGF- β superfamily with an unpaired cysteine residue that may not exist as a dimer. Nevertheless, it has been suggested that, in GDF-3 and GDF-9 (which also lack such a cysteine residue) hydrophobic contacts between the two monomer subunits may promote dimer formation (26). Whereas the carboxy terminus of the

TGF- β family is usually CX1CX1, *ebaf* has a longer COOH-terminal sequence, CX1CX19 (Fig. 5). In addition, the members of the TGF- β superfamily are synthesized as preproproteins, which are cleaved at RXXR site to release the mature form of the protein. The predicted protein of *ebaf* exhibits two such RXXR sites that are located at amino acid residues of 73-76 and 131-134, respectively (Fig. 5). If one of these sequences is the cleavage site, a mature protein of 294 and 236 amino acids should be produced. The deduced amino acid sequence of lefty also contained two potential cleavage sites at amino acid residues of 74-77 and 132-135 with mature proteins of 291 and 233 amino acids (24). In the case of lefty, the expression of the protein in 293T cells led to formation of a nonsecretory, 42-kD protein which is the size of the preproprotein (24). Expression in BALB/3T3 cells, on the other hand, led to the release of processed, 25- and 32-kD proteins in the conditioned media of




Figure 8. Chromosomal localization of *ebaf*. Partial karyotype of G-banded chromosome 1 is shown along with the same chromosome hybridized with FITC-labeled *ebaf* cDNA, indicating that this gene is mapped at 1q42.1 (arrowhead). Ideogram of the long arm of human chromosome 1 (G-banding at 550 bands level) shows the precise location of *ebaf* gene (arrowhead).

G-banding of chromosome 1s and the same chromosomes hybridized with FITC-labeled *ebaf* gene were compared to determine the location of the hybridization signals. Fig. 7 shows the physical mapping of FITC-labeled *ebaf* gene to the long arm of chromosome 1. A schematic diagram of the high-resolution G-banded chromosome 1q (550 bands) shows the precise location of the *ebaf* gene on chromosome 1, at band q42.1 (Fig. 8).

In addition to the sequence similarity, *ebaf* and *lefty* share several other features. In situ hybridization revealed that the transient expression of *ebaf* was primarily confined to the mesenchymal cells of the endometrial stroma rather than the epithelium or endothelium. The *lefty* mRNA was also transiently expressed in the mesoderm in the left half of the gastrulating mouse embryo just before the first sign of lateral symmetry appeared (24). *ebaf* gene is located on human chromosome 1. Similarly, the location of the *lefty* has been provisionally assigned to chromosome 1 (24). Taken together, the available data show that *ebaf* is a new member of the TGF- β superfamily. In view of chromosomal localization, great homology in the cDNA, and the predicted protein sequences and other structural features, *ebaf* may represent the human homolog of mouse *lefty*.

Steroid hormones are the systemic signals whose withdrawal leads to endometrial bleeding and tissue shedding. On the other hand, *ebaf* may be a member of the family of genes that locally participates in the expression of these characteristic attributes of human endometrium. Recent evidence suggests that expression of certain members of matrix metalloproteinase family (MMP) that degrade extracellular matrix appears at defined and distinct time periods during menstrual bleeding (31, for a recent review see reference 4). These findings support the viewpoint that specific genes exist in human endometrium that locally regulate the processes leading to endometrial bleeding. *ebaf* may be a component of the molecular repertoire that locally participates in normal menstrual as well as abnormal endometrial bleeding.

Acknowledgments

The authors are grateful to Marek Wlock, the coordinator at the Tissue Procurement Bank in the Core Facility of the Moffitt Cancer Center for providing the normal tissues.

This work was supported by Public Health Research Grant CA46866 (to S. Tabibzadeh).

References

1. Finn, C.A. 1987. Why do women and some other primates menstruate? *Perspect. Biol. Med.* 30:566-574.
2. Markee, J.E. 1940. Menstruation in intraocular endometrial transplants in the Rhesus monkey. *Contrib. Embryol.* 28:219-308.
3. Tabibzadeh, S. 1994. Cytokines and hypothalamic-pituitary-ovarian-endometrial axis. *Hum. Reprod. Updates.* 9:947-967.
4. Tabibzadeh, S. 1995. Signals and molecular pathways involved in apoptosis with special emphasis on human endometrium. *Hum. Reprod. Updates.* 1:303-323.
5. Tabibzadeh, S. 1996. The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodeling. *Mol. Hum. Reprod.* 2:77-92.
6. Bayer, S.R., and A.H. DeCherney. 1993. Clinical manifestations and treatment of dysfunctional uterine bleeding. *JAMA (J. Am. Med. Assoc.)* 269:1823-1828.
7. Jacobs, A., and E.B. Butler. 1965. Menstrual blood loss in iron deficiency anaemia. *Lancet.* ii:407-409.
8. Hallberg, L., A. Hogdahl, L. Nilsson, and G. Rybo. 1966. Menstrual blood loss: a population study. *Acta Obstet. Gynecol. Scand.* 45:320-351.
9. Fraser, I.S., M. Hickey, and J.-Y. Song. 1996. A comparison of mechanisms underlying disturbances caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. *Hum. Reprod. (Oxf.)* 11:165-178.
10. Wathen, P.I., M.C. Henderson, and C.A. Witz. 1995. Abnormal uterine bleeding. *Med. Clin. North Am.* 79:329-342.
11. Hillard, T.C., N.C. Siddie, M.I. Whitehead, D.I. Fraser, and J. Pryse-Davies. 1992. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. *Am. J. Obstet. Gynecol.* 167:1-7.
12. Archer, D.F., J.H. Pickar, and F. Bottiglion. 1994. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. *Obstet. Gynecol.* 83:686-692.
13. Ober, W.B. 1977. Effects of oral and intrauterine administration of contraceptives on the uterus. *Hum. Pathol.* 8:513-526.
14. Noyes, R.W., and A.T. Hertig. 1950. Dating the endometrial biopsy. *Fertil. Steril.* 1:3-25.
15. Liang, P., and A.B. Pardee. 1992. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science (Wash. DC)* 257:967-971.
16. Liang, P., D. Bauer, L. Averbouch, P. Warthoe, M. Rohrwild, H. Muller, M. Strauss, and A.B. Pardee. 1995. Analysis of altered gene expression by differential display. *Methods Enzymol.* 254:304-321.
17. Marchuck, D., M. Drum, A. Saulino, and F.S. Collins. 1991. Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. *Nucleic Acids Res.* 19:1154.
18. Hadjeb, N., and G.A. Berkowitz. 1996. Preparation of T-overhang vectors with high PCR product cloning efficiency. *Biotechniques.* 20:20-22.
19. Sanger, F., S. Nicklen, and A.R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463-5467.
20. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159.
21. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. *Molecular Cloning: A Laboratory Manual*. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
22. Miller, M.A., P.E. Kolb, and M.A. Raskind. 1993. A method for detection of multiple mRNAs using digoxigenin and radioisotopic cRNA probes. *J. Histochem. Cytochem.* 41:1741-1750.
23. Panoskaltis-Mortari, A., and R.P. Bucy. 1995. In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. *Biotechniques.* 18:300-307.
24. Meno, C., Y. Saijoh, H. Fujii, M. Ikeda, T. Yokoyamas, M. Yokoyamas, Y. Toyoda, and H. Hamada. 1996. Left-right asymmetric expression of the TGF- β family member *lefty* in mouse embryos. *Nature (Lond.)* 381:151-155.
25. Bouillet, P., M. Qulad-Abdelghani, S. Vicaire, G.-M. Garnier, B. Shuh-baur, P. Dolle, and P. Chambon. 1995. Efficient cloning of cDNAs of retinoic acid-responsive genes in P19 embryonal carcinoma cells and characterization of a novel mouse gene, *Stra1* (mouse LERK/Eplg2). *Dev. Biol.* 170:420-433.
26. Kingsley, D.M. 1994. The TGF- β superfamily: new members, new receptors, and new genetic tests of function in different organisms. *Genes Dev.* 8:

133–146.

27. Daopin, S., K.A. Piez, Y. Ogawa, and D.R. Davies. 1992. Crystal structure of transforming growth factor- β 2: an unusual fold in the superfamily. *Science (Wash. DC)*. 257:369–373.

28. McDonald, N.Q., and W.A. Hendrickson. 1993. A structural superfamily of growth factors containing a cystine knot motif. *Cell*. 73:421–424.

29. McPherron, A., and S.-J. Lee. 1993. GDF-3 and GDF-9: two new members of the transforming growth factor- β superfamily containing a novel pattern of cysteines. *J. Biol. Chem.* 268:3444–3449.

30. Jones, C.M., D. Simon-Chazottes, J.-L. Guenet, and B.L.M. Hogan.

1992. Isolation of Vgr-2, a novel member of the transforming growth factor- β -related gene family. *Mol. Endocrinol.* 6:1961–1968.

31. Rodgers, W.H., L.M. Matrisian, L.C. Guidice, B. Dsupin, P. Cannon, C. Svitek, F. Gorstein, and K.G. Osteen. 1994. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. *J. Clin. Invest.* 94:946–953.

32. Kozak, M.J. 1989. The scanning model for translation: an update. *Cell Biol.* 108:229–241.

33. Higgins, D.G., and P.M. Sharp. 1988. CLUSTAL: a package for performing multiple sequence alignments on a microcomputer. *Gene*. 73:237–244.